Genome Square
UK, GB · 1 known investors
Find your way into Genome Square
GenoME develops liquid biopsy tests using DNA methylation biomarkers for early disease detection and monitoring, particularly in cancer diagnostics. The company's pipeline identifies novel biomarkers and delivers rapid, cost-effective PCR tests for applications including companion diagnostics and disease monitoring.
Investors · 1
Frequently asked questions
- What does Genome Square do?
- GenoME develops liquid biopsy tests using DNA methylation biomarkers for early disease detection and monitoring, particularly in cancer diagnostics. The company's pipeline identifies novel biomarkers and delivers rapid, cost-effective PCR tests for applications including companion diagnostics and disease monitoring.
- Who are Genome Square's investors?
- Genome Square's investors include Clarendon Fund Managers Ltd..
- Where is Genome Square headquartered?
- Genome Square is headquartered in UK, GB.